Friday, July 10, 2026

pharma · Critical Limb Ischemia (CLI) · Sarcoma · DSGN

Lxo Ireland Designated

Lxo Ireland Designated is a pharma organization headquartered in CARLSBAD, CA, IE. It trades on NYSE under ticker DSGN. Primary therapeutic focus areas include Critical Limb Ischemia (CLI), Sarcoma, Friedreich Ataxia, HP

CARLSBAD, CA, IE HQ
Public company Type
DSGN · NYSE Ticker
Company details
Clinical program

GLA-SE

Phase 1 · mab · Merkel Cell Carcinoma

GLA-SE for Merkel Cell Carcinoma is a Phase 1 program (mab) at Lxo Ireland Designated Activity Company with 1 ClinicalTrials.gov record(s).

Internal code IDC-G100-2013-001

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Lxo Ireland Designated Activity Company
Phase
Phase 1
Modality
mab
Indication
Merkel Cell Carcinoma
Status
completed
Trials
1

Clinical trials